48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial

Table 1

	DTG+ABC/3TC change from baseline* (N=414)	TDF/FTC/EFV change from baseline* (N=419)	Geometric Mean Ratio**	[95% CI for the ratio] p-value
Bone-specific alkaline phosphatase	15%	60%	0.720	[0.685-0.756] <0.001
C-terminal telopeptide for type 1 collagen	33%	68%	0.789	[0.747-0.832] <0.001
Osteocalcin	22%	48%	0.827	[0.779-0.878] <0.001
Procollagen type 1 N-propeptide	30%	66%	0.784	[0.749- 0.821] <0.001
Vitamin D (25-hydroxy-Vitamin D)	-7%	-10%	1.036	[0.970-1.107] P=0.292

*adjusted percent change from baseline=100 X adjusted geometric mean of (week 48/baseline)-100
**GMR= (DTG+ABC/3TC+100) / (TDF/FTC/EFV+100)

ISSN: 1471-2334